Volume 32, Issue 150 (January & February 2024)                   J Adv Med Biomed Res 2024, 32(150): 33-40 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jafari S, Khalili Mahani S, Mohsen-Pour N. Comparison of the Effect of Duloxetine and Imipramine in the Treatment of Patients with Diarrhea Dominant Irritable Bowel Syndrome. J Adv Med Biomed Res 2024; 32 (150) :33-40
URL: http://journal.zums.ac.ir/article-1-7361-en.html
Comparison of the Effect of Duloxetine and Imipramine in the Treatment of Patients with Diarrhea Dominant Irritable Bowel Syndrome
Sattar Jafari * 1, Soudeh Khalili Mahani2 , Neda Mohsen-Pour3
1- Dept. of Internal Medicine, Vali-e- Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran , Jafari.sattar@gmail.com
2- Dept. of Internal Medicine, Vali-e- Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
3- Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
Abstract:   (378 Views)

Background & Objective:  Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by changes in bowel movements and abdominal pain in the absence of structural disorders. Although effective treatment for irritable bowel syndrome is not yet available. One of the treatments is the low-dose antidepressants, depending on the type and severity of the disease. This study was performed to compare the effect of selective serotonin-norepinephrine reuptake inhibitors including duloxetine and imipramine from a tricyclic antidepressant.
Materials & Methods: forty-eight definitively diagnosed IBS patients (based on Rome III criteria) were examined in 2 groups of men and women. Patients in the control group were treated with Dicyclomine and Imipramine while the case group received dicyclomine and duloxetine. The outcomes were measured before and 3 months after treatment to determine and compare the improvement in responses (mainly diarrhea).
Results: Duloxetine could significantly improve the symptoms such as abdominal pain in females (P-value: 0.01) and males (P-value: 0.001), bloating in females (P-value: 0.004) and incomplete defecation in females (P-value: 0.001) and in males (P-value: 0.007). The side effects of this drug were, however, higher than Imipramine. The introduction of more appropriate treatment requires further studies on a larger sample size to assess the symptoms and the side effects.
Conclusion: Based on the effect of duloxetine on this clinical results, it is recommended as an effective treatment in controlling of abdominal pain, bloating, and incomplete defecation.

Keywords: Irritable bowel syndrome, diarrhea, Duloxetine hydrochloride, Imipramine, Abdominal pain
Full-Text [PDF 563 kb]   (172 Downloads)    
Type of Study: Original Article | Subject: Clinical medicine
Received: 2023/09/30 | Accepted: 2023/12/16 | Published: 2024/01/30
References
1. Arasteh P, Maharlouei N, Eghbali SS, Amini M, Lankarani KB, Malekzadeh R. A comprehensive look at irritable bowel syndrome and its associated factors considering the Rome IV criteria: a penalized smoothly clipped absolute deviation regression approach in the pars cohort study.Middle East J Dig Dis. 2018;10(3):149. [DOI:10.15171/mejdd.2018.104] [PMID] []
2. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol . 2021;116(1):17-44. [DOI:10.14309/ajg.0000000000001036] [PMID]
3. Halpert AD, Thomas AC, Hu Y, Morris CB, Bangdiwala SI, Drossman DA. A survey on patient educational needs in irritable bowel syndrome and attitudes toward participation in clinical research. J Clin Gastroenterol. 2006;40(1):37-43. [DOI:10.1097/01.mcg.0000190759.95862.08] [PMID]
4. Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol. 2021;6(2):139-48. [DOI:10.1016/S2468-1253(20)30212-0] [PMID]
5. Heymann-Mönnikes I, Arnold R, Florin I, Herda C, Melfsen S, Mönnikes H. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol. 2000;95(4):981-94. https://doi.org/10.1016/S0002-9270(00)00729-2 [DOI:10.1111/j.1572-0241.2000.01937.x] [PMID]
6. Coffin B, Duboc H. Diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56(3):419-35. [DOI:10.1111/apt.17064] [PMID]
7. Jafarzadeh E, Shoeibi S, Bahramvand Y, et al. Turmeric for treatment of irritable bowel syndrome: A systematic review of population-based evidence. Iran J Public Health. 2022;51(6):1223. [DOI:10.18502/ijph.v51i6.9656] [PMID] []
8. van Kessel L, Teunissen D, Lagro-Janssen T. Sex-gender differences in the effectiveness of treatment of irritable bowel syndrome: a systematic review. Int J Gen Med. 2021;14:867. [DOI:10.2147/IJGM.S291964] [PMID] []
9. Lackner JM, Jaccard J. Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome. J Consult Clin Psychol. 2021;89(5):435. [DOI:10.1037/ccp0000648] [PMID] []
10. Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA. 2021;325(9):865-77. [DOI:10.1001/jama.2020.22532] [PMID]
11. Lewis-Fernández R, Lam P, Lucak S, et al. An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder. J Clin Psychopharmacol. 2016;36(6):710-5. [DOI:10.1097/JCP.0000000000000599] [PMID]
12. Kaplan A, Franzen MD, Nickell P, Ransom D, Lebovitz PJ. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract. 2014;18(1):11-5. [DOI:10.3109/13651501.2013.838632] [PMID]
13. Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope Jr HG, Hudson JI. Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study. Hum Psychopharmacol. 2009;24(5):423-8. [DOI:10.1002/hup.1038] [PMID]
14. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32(7):1221-33. [DOI:10.1016/j.clinthera.2010.07.002] [PMID]
15. Xie C, Tang Y, Wang Y, et al. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One. 2015;10(8):e0127815. [DOI:10.1371/journal.pone.0127815] [PMID] []
16. Masand PS, Gupta S, Schwartz TL, et al. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Prim Care Companion J Clin Psychiatry . 2002;4(1):12. [DOI:10.4088/PCC.v04n0105] [PMID] []
17. Keshavarz AA, Rezaei M, Rezaei E, Khaledi S, KHAN MZ. The efficacy of fluoxetin and doxepin in treatment of irritable bowel syndrome. J Kermanshah Univ Med Sci. 2009;13(2):e79797
18. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers A-M, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-103. [DOI:10.1136/gut.2005.077503] [PMID] []
19. Grover M, Camilleri M. Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. J Gastroenterol. 2013;48(2):177-81. [DOI:10.1007/s00535-012-0726-5] [PMID] []
20. Fadgyas-Stanculete M, Buga AM, Popa-Wagner A, Dumitrascu DL. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry. 2014;2(1):1-7. [DOI:10.1186/2049-9256-2-4] [PMID] []
21. Vahedi H, Ansari R, Mir-Nasseri MM, Jafari E. Irritable bowel syndrome: a review article. Middle East J Dig Dis. 2010;2(2):66.
22. Foroutan H, Taheri AG, Houshangi H, Mohammadi H. Effects of fluoxetine, nortriptyline, and amitriptyline in IBS patients. Feyz. 2002; 6(1): 49-55
23. Abdul-Baki H, El Hajj II, ElZahabi L, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol. 2009;15(29):3636. [DOI:10.3748/wjg.15.3636] [PMID] []
24. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53(1):108-15. [DOI:10.1007/s10620-007-9830-4] [PMID]
25. Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion. 2014;89(4):253-67. [DOI:10.1159/000362405] [PMID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb